Table 2. Multivariate Cox regression analysis of recurrence-free survival in each cohort.
| Variables | Multivariate analysis |
||
|---|---|---|---|
| HR | 95% CI of HR | P-value | |
| Discovery cohort, (n = 104) | |||
| BCSigLnc-12 | |||
| Low | 1 (reference) | ||
| High | 2.81 | 1.97–4.01 | 1.3e-08 |
| Age | 1.15 | 0.60–2.20 | 0.683 |
| ER | |||
| ER− | 1 (reference) | ||
| ER+ | 0.30 | 0.15–0.60 | 5.69e-04 |
| Grade | |||
| G1 | 1 (reference) | ||
| G2 | 0.73 | 0.16–3.46 | 0.694 |
| G3 | 0.82 | 0.17–3.89 | 0.806 |
| Size | |||
| <=2 cm | 1 (reference) | ||
| >2 cm | 0.72 | 0.31–1.69 | 0.447 |
| Lymph node | |||
| Lymph node− | 1 (reference) | ||
| Lymph node+ | 3.95 | 1.72–9.06 | 0.001 |
| Test cohort-2, (n = 77) | |||
| BCSigLnc-12 | |||
| Low | 1 (reference) | ||
| High | 1.85 | 1.0004–3.42 | 0.0498 |
| Age | 0.85 | 0.26–2.75 | 0.786 |
| Grade | |||
| G1 | 1 (reference) | ||
| G2 | 1.313 | 0.138–13.45 | 0.818 |
| G3 | 1.314 | 0.137–13.61 | 0.819 |
| Size | |||
| <=2 cm | 1 (reference) | ||
| >2 cm | 2.74 | 0.55–13.74 | 0.221 |
| Test cohort-3, (n = 88) | |||
| BCSigLnc-12 | |||
| Low | 1 (reference) | ||
| High | 1.074 | 0.531–2.173 | 0.842 |
| Grade | |||
| G1 | 1 (reference) | ||
| G2 | 1.271 | 0.179–9.046 | 0.811 |
| G3 | 1.472 | 0.401–5.400 | 0.560 |
| ER | |||
| ER− | 1 (reference) | ||
| ER+ | 0.673 | 0.313–1.446 | 0.310 |
| Lymph node | |||
| Lymph node− | 1 (reference) | ||
| Lymph node+ | 2.553 | 1.104–5.903 | 0.028 |
| Her2 | |||
| Her2− | 1 (reference) | ||
| Her2+ | 1.243 | 0.612–2.523 | 0.548 |
Abbreviations: HR, hazard ratio; CI, confidence interval.